Conduit Cages and Fibergraft BG Putty
Assess Clinical and Radiographic Outcomes of Conduit Cages and Fibergraft in Cervical and Lumbar Procedures
The Conduit cages are intended to restore the intervertebral height and to facilitate the intervertebral body fusion in the cervical and lumbar spine in skeletally mature patients with degenerative disc disease and instabilities at one or more levels of the spine. The Fibergraft Bioactive Glass (BG) is engineered to mimic the body's natural bone healing process. While previous studies have described the use of conduit cages in interbody fixation procedures, these studies did not specifically study the clinical and radiographic outcomes of patients who have received these implants in addition to Fibergraft. We aim to recruit patients with degenerative disc disease, and instabilities at one to multilevel contiguous levels between C2-T1 and 1-2 contiguous levels between L2-S1 of the spine with accompanying radicular symptoms, ruptured or herniated discs, and pseudarthrosis and spondylodesis. We will then follow these patients for a duration of two years to report their clinical and radiographic outcomes to determine fusion, complication rate, and revision surgeries if any.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Adult patients with spinal conditions mentioned in inclusion/exclusion criteria
Description
Inclusion Criteria:
- Age ≥ 18 years
- Have a radiograph-based diagnosis of degenerative disc disease, ruptured or herniated discs,
- Pathology of the cervical or lumbar spine.
- Pathology to be between C2-T1 in the cervical group.
- Pathology to be between L2-S1 in the lumbar group.
- Patients with 1-2 contiguous levels in both ACDF and Lumbar groups.
- Patients receiving the surgery/devices as standard of care prescribed by the treating physician.
Exclusion Criteria:
- Patients < 18 years
- BMI > 40 kg/m2 to be excluded
- Patients with a bone density (DEXA) score of <2.0 to be excluded
- 3 or more levels for ACDF or Lumbar interbody to be excluded
- Patients with previous pseudoarthrosis or failed spondylodesis to be excluded
- Current smokers and patients who quit smoking within 6 weeks prior to presentation will be excluded
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_ONLY
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fusion
Time Frame: 2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
We will assess fusion with regular x-rays and CT scans at 1 and 2-year postoperatively. |
2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual Analog Scale (VAS)
Time Frame: 2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
We will have patients fill out validated tools for PROs to assess how the patient is doing postoperatively |
2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
|
Oswestry Disability Index
Time Frame: 2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
We will have patients fill out validated tools for PROs to assess how the patient is doing |
2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
|
SF-12
Time Frame: 2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
We will have patients fill out validated tools for PROs to assess how the patient is doing |
2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
|
Neck Disability Index
Time Frame: 2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
We will have patients fill out validated tools for PROs to assess how the patient is doing |
2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Nitin Agarwal, MD, University of Pittsburgh
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STUDY24040009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.